Rx Rundown: Novartis, Boston Scientific, Illumina and more
Check out this week’s medical marketing news, people on the move and industry chatter.
Source: mmm-online.com
📰 Al Robichaud News
Al Robichaud News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Al Robichaud. Real-time updates on events, politics, business and more.
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE and expected data read-outs for SAGE-718 and SAGE-324 in 2024 Approximately 40% workforce reduction supports focus on agile...
Source: marketscreener.com
Sage Therapeutics to lay off 40% of staff as it gears up for launch of postpartum-depression treatment
Sage Therapeutics Inc. said Thursday it is reorganizing its business operations and workforce as it gears up for the launch of its postpartum-depression...
Al Robichaud Jim Doherty Sage Therapeutics Inc Sage Therapeutics Medicinal Chemistry Pre Clinical Scientific Advisory
Source: marketwatch.com
Sage Therapeutics to cut about 188 jobs after depression drug setback
The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market. Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth. As part of the reorganization, Sage said its Chief Scientific Officer Al Robichaud will leave the com...
Shilpi Majumdar Al Robichaud Shounak Dasgupta Christy Santhosh Drug Administration Sage Therapeutics
Source: yahoo.com
Sage Therapeutics to lay off about 40 percent of its workforce
The job cuts come after the FDA gave only limited approval to the Cambridge company’s new treatment for depression.
Source: bostonglobe.com
Sage Therapeutics Cutting 40% of Staff in Restructuring >SAGE
By Colin Kellaher Sage Therapeutics plans to slash 40% of its workforce in a restructuring after the biopharmaceutical company and partner Biogen failed to...
Source: marketwatch.com
Sage Therapeutics trims staff by 40% following depression drug setback
The cuts, including several C-suite exits, come in the wake of the FDA’s decision not to approve Sage and partner Biogen’s drug for major depression.
Source: mmm-online.com
Former assistants meet up when Concord-Carlisle faces Lexington to restart Thanksgiving rivalry
Thursday’s 10 a.m. Concord-Carlisle/Lexington game is being prepared for with the usual special treatment. It’s not only the rebirth of a long-played series.
Source: wickedlocal.com